ArticleNPJ precision oncology2022

Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma.

James M Cleary et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.